Navigation Links
Wellmune WGP supplementation alleviates
Date:4/8/2008

SAN DIEGO, CA. April 9, 2008 Wellmune WGP, a natural immune-enhancing ingredient from Biothera, reduced the incidence of fever and eliminated the need for study subjects to miss work or school due to the cold-like symptoms, researchers reported today at the 2008 Experimental Biology annual meeting.

Don Cox, Ph.D., Vice President of Research & Development for Biotheras Healthcare Group, said, This studys results are exciting because they show the potential for Wellmune WGP to naturally enhance the bodys innate immune response to protect against and ameliorate the symptoms of something that every one of us encountersthe common cold. These results are consistent with numerous other immune health studies conducted with our ingredient, and indicate the real-life benefits that Wellmune WGP supplementation can provide.

The research will be presented at the Poster Sessions starting 9:00 am on April 9th by Douglas Kalman, Ph.D., RD, FACN, a Director at Miami Research Associates, which conducted the study for Biothera. An abstract of the study is available at www.biothera.com/healthcare.

The double-blind, placebo-controlled study was conducted during the cold season with 40 healthy subjects, aged 18-65. The subjects were treated daily with either 250mg of Wellmune WGP or a placebo for 90 days. Wellmune WGP is a natural carbohydrate that activates key immune cells, including macrophages and neutrophils, to more quickly recognize and kill foreign challenges. The product engages the bodys natural defenses to promote health, wellness and vitality. In contrast with the placebo group, study participants who received Wellmune WGP daily reported:

  • No incidence of medically verified fever.

  • An increase in general health markers, including physical energy and emotional well-being, as measured by a clinically validated health survey questionnaire (SF-36v-2).

  • No need to take a sick day off of work or school (compared with 1.38 days of work/school missed for the placebo group).

In addition, although there were no differences between groups in the number of colds, at the end of the 12-week test period the Wellmune WGP-supplemented group exhibited significant improvements in Physical Component Summary scores as defined in the SF-36v-2 health survey.


'/>"/>

Contact: Dave Walsh
651-256-4606
Strategic Communications
Source:Eurekalert

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... NEW YORK , Jan. 12, 2017  New research ... around the office of the future.  1,000 participants were simply ... last three months which we may consider standard issue.  Insights ... office of 2017 were also gathered from futurists and industry ... and Dr. James Canton .  Some ...
(Date:1/6/2017)... Calif. , Jan. 6, 2017  Privately-held ... safety studies in healthy volunteers of a novel ... to treat acute pancreatitis. Acute ... typically a mild disorder, but can be very ... failure and sepsis, where extended hospital stays, time ...
(Date:1/4/2017)... 4, 2017  CES 2017 – Valencell , ... today announced the launch of two new versions ... highly-accurate biometric sensor modules that incorporate the best ... and expertise. The two new designs include Benchmark ... hearables, and Benchmark BW2.0, a 2-LED version of ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... 19, 2017  Market Research Future has a half cooked research ... Biopsy is growing rapidly and expected to reach USD 450 Million ... ... Biopsy Market has been assessed as a swiftly growing market and ... in the coming future. There has been a tremendous growth in ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... for pharmaceutical research and development (R&D), today announced the launch of ... and interpretation for the rapidly evolving field of precision medicine. , ...
(Date:1/19/2017)... AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: AQB), ... and a majority-owned subsidiary of Intrexon Corporation (NYSE: ... listing of its common shares on the NASDAQ Stock ... "AquaBounty,s listing on NASDAQ represents an important milestone ... the U.S. markets as we advance plans for commercial ...
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical Research ... drug and device development, and Prism Clinical Research , a leader in ... Verified Clinical Trials (VCT) has been selected by both companies as ...
Breaking Biology Technology: